SecBot SecBot
PRESS-RELEASE ·Filed Mar 10, 2026

PVLA

Palvella Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

This is a pre-commercialization awareness effort ahead of potential FDA approval of QTORIN™ rapamycin. Traders should monitor upcoming clinical trial data (e.g., TOIVA study) and regulatory milestones as potential catalysts. Insider buying in the past 30 days may signal confidence in future developments.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$142.11
T+0 close · Mar 10, 2026 · via day close
Latest settled
−18.78%
T+60 · $115.42
Vs SPY
−30.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 10 $142.11entry
  2. T+1 · 8mo ago −1.70%α −1.60% · $139.69
  3. T+5 · 8mo ago −15.00%α −14.09% · $120.80
  4. T+20 · 7mo ago −13.33%α −13.17% · $123.17
  5. T+60 · 6mo ago −18.78%α −30.46% · $115.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics launched the 'BEYOND mLM' disease awareness campaign and website (BEYONDmLM.com) to educate patients, caregivers, and healthcare providers about microcystic lymphatic malformations (microcystic LMs), a rare and debilitating condition with no FDA-approved therapies. The campaign was developed in collaboration with leading nonprofit organizations and clinical experts in the vascular anomalies community.

Key Facts

  • Palvella launched BEYONDmLM.com, an educational campaign and website focused on microcystic lymphatic malformations (microcystic LMs).
  • The campaign was developed in partnership with five key nonprofit organizations: CaNVAS, LGDA, LE&RN, PeDRA, and VAccess.org.
  • Microcystic LMs affect over 30,000 diagnosed patients in the U.S. and are characterized by malformed lymphatic vessels causing chronic leakage, bleeding, and recurrent infections.
  • There are currently no FDA-approved treatments for microcystic LMs.
  • Palvella’s lead investigational product, QTORIN™ rapamycin gel, is in development for this condition.

Financial Impact

No direct financial impact disclosed; campaign is educational and awareness-focused.

Risk Factors

  • No guarantee that increased awareness will translate into future product adoption.
  • QTORIN™ rapamycin remains investigational and may not achieve regulatory approval or commercial success.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3252673

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 10, 2026